BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Trials

HiRO Partners with South Korea’s CHA Bundang Medical Center to Advance Global Clinical Trials

Harvest Integrated Research Organization (HiRO), a boutique global clinical research organization (CRO) providing cross-border clinical trial sol...

December 16, 2024 | News

ADELA Phase III Trial Combines Elacestrant and Everolimus to Tackle Advanced ER+/HER2- Breast Cancer with ESR1 Mutations

ADELA, an international phase III study being conducted across multiple countries, combines elacestrant with everolimus to treat advanced ER+/HER2- breas...

December 13, 2024 | News

CureGene Secures NMPA Approval for Clinical Trial of Novel Antiplatelet Drug CG-0255 in China

CureGene Pharmaceutical ("CureGene"), a biotechnology company dedicated to innovative treatments for critical unmet medical needs in cardio-cerebrovascular...

December 13, 2024 | News

CellProthera and SKGH Forge Alliance to Advance CD34+ Cell Therapy for Ischemic Diseases in Japan

CellProthera, a regenerative cell therapy developer specializing in ischemic diseases, announced a new memorandum of understanding with Shonan Kamakur...

December 13, 2024 | News

SK bioscience to Launch Phase 1/2 Trials for First mRNA Vaccine Candidate in Australia

SK bioscience’s first mRNA vaccine candidate is expected to enter clinical trials in Australia in February 2025, with interim results expected by 2...

December 13, 2024 | News

GNT Pharma Announces Promising Nelonemdaz Results, Initiates Global Phase 3 Stroke Trials

** IND submitted to the FDA showing significantly improved patient condition when administered within 70 minutes of arrival at the Emergency Room ** *Mult...

December 12, 2024 | News

AstraZeneca and MSD LYNPARZA Shows Sustained Survival Benefit at Six Years in High-Risk Early Breast Cancer

87.5% of patients treated with LYNPARZA were alive at six years vs. 83.2% in the comparator arm First and only PARP inhibitor to improve survival in...

December 12, 2024 | News

Duke Street Bio Initiates Phase I Trial of Highly Selective PARP1 Inhibitor DSB2455 for Solid Tumours

Duke Street Bio Ltd, a precision medicine biotech developing next-generation small molecule cancer therapies, is pleased to announce that the first patient...

December 12, 2024 | News

TransThera Presents Promising Phase I Results for TT-01488 at 2024 ASH Annual Meeting

TransThera Sciences (Nanjing), Inc. (the "TransThera"), a clinical demand-oriented, registrational clinical stage biopharmaceutical company focusing on dis...

December 11, 2024 | News

Actinogen Expands Alzheimer’s Trial Across Australia and US, Eyes Interim Results in 2025

Late-stage trial in Alzheimer's opens 10 sites in US, with results due in 2025 and 2026 Appoints US-based Chief Commercial Officer, Andrew Udell X...

December 10, 2024 | News

Skyhawk Therapeutics Gains Australian Approval to Extend SKY-0515 Huntington’s Disease Trial to 12 Weeks

Australian Human Research Ethics Committees approves SKY-0515 treatment for up to 12 weeks in the company's ongoing Phase 1 trial in patients with Hun...

December 10, 2024 | News

Hansa Biopharma Completes Phase 3 Trial Enrollment Ahead of Schedule for Rare Autoimmune Disease

Hansa Biopharma, "Hansa" announced it has completed the enrolment of patients in the GOOD-IDES-02 trial, a global pivotal Phase 3 trial in anti-glomerular ...

December 06, 2024 | News

NTC Announces Positive Phase II Results for NTC014 in Bacterial Conjunctivitis Treatment

NTC, an international R&D focused pharmaceutical company headquartered in Italy, presents positive results from Phase II MIRAKLE study, a mul...

December 06, 2024 | News

Thermo Fisher Enhances Cell Therapy Manufacturing with CTS Detachable Dynabeads™ for CD4+ and CD8+ T Cell Isolation

T cell isolation and controlled release delivers flexibility and control in process development, clinical trials and commercial manufacturing Thermo Fishe...

December 05, 2024 | News

Stay Connected